MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TEM made $334,206,000 in revenue. -$79,982,000 in net income. Net profit margin of -23.93%.

Income Overview

Revenue
$334,206,000
Net Income
-$79,982,000
Net Profit Margin
-23.93%
EPS
-$0.46
Unit: Dollar
Revenue Breakdown
    • Genomic
    • Data And Services

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Total net revenue
334,206,000 314,635,000 255,737,000 173,250,000
Cost of revenues-Genomic
98,643,000 99,756,000 84,783,000 57,508,500
Cost of revenues-Data And Services
25,621,000 19,840,000 15,751,000 15,861,000
Technology research and development
38,087,000 34,482,000 33,391,000 29,465,500
Research and development
44,960,000 41,619,000 35,874,000 26,976,000
Selling, general and administrative
187,891,000 180,712,000 154,627,000 95,426,000
Total cost and operating expenses
395,202,000 376,409,000 324,426,000 225,237,000
Loss from operations
-60,996,000 -61,774,000 -68,689,000 -51,987,000
Interest income
4,600,000 1,093,000 1,813,000 2,288,500
Interest expense
15,399,000 21,579,000 18,003,000 13,298,500
Loss on debt extinguishment
-12,034,000 ---
Other income (expense), net
2,605,000 41,729,000 -27,455,000 25,453,000
Loss before (provision for) benefit from income taxes
-81,224,000 -40,531,000 -112,334,000 -37,544,000
(provision for) benefit from income taxes
276,000 212,000 -46,180,000 -
Gains (losses) from equity method investments
1,518,000 -2,100,000 -1,883,000 -1,268,000
Provision for income taxes
---66,500
Net loss
-79,982,000 -42,843,000 -68,037,000 -38,878,500
Dividends on series a, b,b-1,b-2,c, d, e, f, g,g-3,andg-4preferred shares
0 0 0 13,903,500
Accretion of convertible preferred stock to redemption value
---0
Cumulative undeclared dividends on series c preferred shares
0 0 0 253,000
Net loss attributable to common shareholders, basic
-79,982,000 -42,843,000 -68,037,000 -53,035,000
Earnings per share, basic
-0.46 -0.25 -0.4 0.545
Earnings per share, diluted
-0.46 -0.25 -0.4 0.545
Weighted average number of shares outstanding, basic
174,945 173,381 170,506 -64,044
Weighted average number of shares outstanding, diluted
174,945 173,381 170,506 -64,044
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$79,982,000 Net loss-$79,982,000 Gains (losses) fromequity method...$1,518,000 (provision for) benefitfrom income taxes$276,000 Loss before(provision for) benefit...-$81,224,000 Other income(expense), net$2,605,000 Interest income$4,600,000 Data And Services$81,328,000 Genomic$252,878,000 Loss on debtextinguishment-$12,034,000 Interest expense$15,399,000 Loss from operations-$60,996,000 Total net revenue$334,206,000 Total cost andoperating expenses$395,202,000 Selling, general andadministrative$187,891,000 Research and development$44,960,000 Technology research anddevelopment$38,087,000 Cost ofrevenues-Data And Services$25,621,000 Cost ofrevenues-Genomic$98,643,000

logo-black-svg

Tempus AI, Inc. (TEM)

logo-black-svg

Tempus AI, Inc. (TEM)